CatalYm joins Pfizer in pivotal cachexia push
Shortly after ponsegromab, visugromab is to start phase 2/3.
More conjugates pile into the clinic
J&J, Astra, Pfizer and others move yet more ADCs into human studies.
Novita goes into phase 3
Meanwhile, ASK Pharm challenges Hutchmed in cMet.
ALX's conjugate foray goes clinical
ALX2004 starts phase 1, along with the sixth oncology-focused in vivo Car-T.
Bristol takes its bispecific conjugate into lung cancer
A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
The month ahead: August’s upcoming events
Jazz’s Chimerix buy faces its big test.
Astra’s Neogene investment nosedives
NT-125 is discontinued, while two key Datroway readouts are delayed.
Novel cadherin conjugates enter the clinic
Biopharma's interest in CDH17 and CDH6 continues, courtesy of Lepu and Qilu.
